Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues

María Angustias Muros, Mariela Varsavsky, Pablo Iglesias Rozas, Javier Valdivia, Juan Ramón Delgado, Flavio Forrer, Lisa Bodei, Giovanni Paganelli

Research output: Contribution to journalArticlepeer-review


Objectives: To evaluate the initial response and outcomes (quality of life and presence of side effects) in patients with advanced neuroendocrine tumours (NET) after treatment with radiolabelled somatostatin analogues: 90Y-DOTAT-yr3-octreotide (90Y-DOTATOC) and 177Lu-DOTA-Tyr3- octreotate (177Lu-DOTATATE). Material and methods: The study included 5 patients with advanced NET referred to European centres for treatment with 90Y-DOTATOC and 177Lu-DOTATATE after lack of response to conventional treatment. The mean age was 45.6 years (29-68 years). Response to therapy was assessed according to: (1) RECIST criteria, as complete response, partial response, stable disease or disease progression, (2) post-treatment survival time and (3) quality of life, using the Karnofsky performance index. Results: All patients survived for >20 months after treatment; mean survival time was 28 months. At the time of writing, three of the patients are alive after 20, 26 and 37 months. Partial response was observed in one patient, stable disease in three and disease progression in the fifth patient. A good-to-excellent post-treatment quality of life was observed in all patients. Conclusion: Therapy with radiolabelled somatostatin analogues showed promising results in patients with advanced NET, with a partial response or disease stabilisation in four of the five patients, who have enjoyed an extended survival period and an improved quality of life.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalClinical and Translational Oncology
Issue number1
Publication statusPublished - 2009


  • Neuroendocrine tumours
  • Radiolabelled somatostatin analogues

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues'. Together they form a unique fingerprint.

Cite this